UBS on Swiss equities: Selloff creates an opportunity to reposition By Investing.com

UBS upgraded Swiss equities to 'Attractive' after the SMI fell roughly 15% at its intramonth low and now trades ~16x forward earnings versus a long-term average of 15.8x. UBS highlights a ~3.2% dividend yield (vs near-zero Swiss franc bond yields), favors quality/defensive sectors (health care, staples) and expects currency drag to ease from Q2; Brent crude is near $113/bbl, which remains a headwind. UBS also upgraded European health care to 'Attractive' with a ~2.7% yield and sees the pullback as a constructive entry point for dividend growers and profitability leaders.

Analysis

Swiss large-cap defensives (pharma, staples, high-quality dividend growers) will likely capture relative inflows as a low-volatility yield proxy when geopolitical risk spikes, but that positioning has a clear FX sensitivity: further CHF appreciation would materially shave USD/eur-reported growth for exporters, compressing EPS even if organic margins hold. Energy-import-driven input cost pressure creates a mid-term margin squeeze for domestics and midsized industrial suppliers, amplifying dispersion within the market and making stock selection (margin resilience, FX hedging policies) more important than index exposure.

Key catalysts to watch over the next 1–6 months are: Q2 trading statements where currency hedges surface, SNB signalling on FX interventions or policy adjustment if imported inflation proves persistent, and Brent moves above psychological levels that force cost pass-through debates in earnings calls. Tail risks include rapid escalation of the conflict or a >$20 move in Brent in 60 days that would force both corporate margin revisions and a re-rating of duration-sensitive dividend stocks.

Second-order winners include Zurich- or Geneva-based asset managers and dividend-focused ETFs that may see rebalancing inflows; losers are Switzerland-centric industrial suppliers and energy-sensitive mid-caps with limited hedges. The market action to date suggests a tranche-driven opportunity: accumulate high-quality, cash-generative names selectively on volatility spikes while using short-duration hedges to protect against a rates/FX repricing event.

Consensus underestimates the timing mismatch between operational recovery and reported EPS when currencies reverse: earnings momentum can improve while headline EPS lags for 2–3 quarters, creating windows where valuation multiple expansion occurs before fundamentals catch up — an exploitable asymmetry if entry is timed around FX troughs.

Key Decisions for Investors

• Long EWL (iShares MSCI Switzerland) 3–9 months: buy on a 3–5% intraday pullback, target +15–20% outperformance vs MSCI World, hard stop -10%. Rationale: low-volatility, dividend proxy to capture rotation into quality while inflation/energy risk is elevated.
• Pair trade (3–6 months): Long RHHBY (Roche ADR) 1% position vs Short EWG (iShares Germany ETF) 0.6% position. Expect defensive pharmaceutical outperformance vs cyclical exporters if geopolitics keep risk premia elevated. Risk/reward ~2:1 (upside 20% vs downside 10%) with weekly rolling protective puts on the long leg during large oil spikes.
• Long UBS (UBS) 6–12 months: 1–2% position on weakness below a key technical level, target +25% if flows rotate to dividend growers and wealth management margins re-price; downside (~-15%) if global risk appetite collapses. Use covered calls to fund carry if holding through earnings.
• Options hedge: Buy 3-month Brent call spread (e.g., $100/$120) sized to cover incremental EBITDA hit for a Swiss mid-cap basket — cost limits to <0.5% portfolio notional. This caps tail inflation risk while leaving upside in equities intact.